search
Back to results

Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

Primary Purpose

Viral Conjunctivitis

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
APD-209 Eye drops
APD-209 Placebo Eye drops
Sponsored by
Adenovir Pharma AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Viral Conjunctivitis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

The patients have to meet all of the following criteria to be eligible to enter the study:

  • Willing and able to provide informed consent.
  • Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less 7 days at the time of giving informed consent.
  • Using adequate contraceptive measures

Exclusion Criteria:

  • Known or suspected allergy to any ingredient of the IMP or placebo.
  • Symptoms correlating with EKC since more than 7 days.
  • Diagnosis of other significant disease(s) than EKC in the eye.
  • Diagnosis of bacterial or fungal ocular infections.
  • Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study.
  • Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion.
  • Use of antiviral medications within 7 days prior to inclusion.
  • Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes.
  • Usage of any medication or herbal medicinal product for ocular administration at inclusion.
  • Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period.
  • Known or suspected drug abuse.
  • Usage of contact lenses during the study.
  • Participation in any other interventional clinical study within 30 days prior to inclusion

Sites / Locations

  • Augenklinik Universitätzmedizin Charité
  • Universitätsklinikum Düsseldorf
  • Universitäts-Augenklinik Freiburg
  • Augenklinik Köln, Merheim
  • Universitäts-klinikum Schleswig-Holstein
  • Augenklinik, Universitätsklinikum Tübingen
  • Universitäts-Augenklinik
  • Katowice University Hospital
  • P. Oleksy Centrum Medyczne Uno-Med
  • St Eriks Eye Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

APD-209 Eye drops

APD-209 Placebo Eye drops

Arm Description

APD-209 Eye drops

APD-209 Placebo Eye drops

Outcomes

Primary Outcome Measures

The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo.
Viral load in tear liquid from EKC infected eyes, as measured by the area under the curve (AUC) at 3-14 days from start of treatment.

Secondary Outcome Measures

Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo.
The time point of viral eradication in tear liquid from EKC infected eyes, defined as the time Point when viral load=0 or below the lower limit of quantification (LLOQ).
Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.
Resolution of acute ocular symptoms at each time of assessment, as measured by objective (Investigator-based) assessment of conjunctival discharge and redness.
Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.
Presence and location of opacities at each time of assessment, as measured by slit lamp examination.
Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.
Visual acuity at each time of assessment by use of the logarithm of the Minimum Angle of Resolution (LogMAR) chart.
Assess the frequency of second eye infections.
Occurrence of second eye infection.
Assess the safety and tolerability of APD-209 Eye drops.
Safety variables: adverse events (AEs) (nature and incidence), Physical examination, vital signs, laboratory safety assessments (haematology, clinical chemistry and urinalysis)

Full Information

First Posted
October 31, 2013
Last Updated
November 1, 2016
Sponsor
Adenovir Pharma AB
Collaborators
TFS Trial Form Support
search

1. Study Identification

Unique Protocol Identification Number
NCT01977443
Brief Title
Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)
Official Title
Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
November 2013 (undefined)
Primary Completion Date
September 2016 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Adenovir Pharma AB
Collaborators
TFS Trial Form Support

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A randomized, double-masked, placebo-controlled, multi-centre phase IIa proof-of-concept study to evaluate efficacy and safety of APD-209 Eye drops for treatment of acute phase adenovirus-induced EKC. The aims of the study are to investigate the therapeutic efficacy of APD-209 Eye drops as measured by adenoviral load, time to viral eradication, clinical resolution of EKC (objective and subjective assessments), presence of opacities, visual acuity and frequency of second eye infections, and to assess the safety and tolerability of APD-209 Eye drops in EKC infected eyes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Viral Conjunctivitis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
47 (Actual)

8. Arms, Groups, and Interventions

Arm Title
APD-209 Eye drops
Arm Type
Active Comparator
Arm Description
APD-209 Eye drops
Arm Title
APD-209 Placebo Eye drops
Arm Type
Placebo Comparator
Arm Description
APD-209 Placebo Eye drops
Intervention Type
Drug
Intervention Name(s)
APD-209 Eye drops
Intervention Type
Drug
Intervention Name(s)
APD-209 Placebo Eye drops
Primary Outcome Measure Information:
Title
The primary objective is to assess the adenoviral load in epidemic keratokonjunctivitis (EKC) infected eyes following topical treatment with APD-209 Eye drops compared to placebo.
Description
Viral load in tear liquid from EKC infected eyes, as measured by the area under the curve (AUC) at 3-14 days from start of treatment.
Time Frame
14 days
Secondary Outcome Measure Information:
Title
Assess the time to viral eradication in EKC infected eyes following treatment with APD-209 Eye drops compared to placebo.
Description
The time point of viral eradication in tear liquid from EKC infected eyes, defined as the time Point when viral load=0 or below the lower limit of quantification (LLOQ).
Time Frame
14 days
Title
Evaluate the effect of APD-209 Eye drops on clinical resolution of EKC, as measured by objective and subjective assessment of scaled clinical symptoms, compared to placebo.
Description
Resolution of acute ocular symptoms at each time of assessment, as measured by objective (Investigator-based) assessment of conjunctival discharge and redness.
Time Frame
14 days
Title
Evaluate the presence of opacities (quantitatively and qualitatively) following treatment with APD-209 Eye drops compared to placebo.
Description
Presence and location of opacities at each time of assessment, as measured by slit lamp examination.
Time Frame
14 days
Title
Assess the visual acuity following treatment with APD-209 Eye drops compared to placebo.
Description
Visual acuity at each time of assessment by use of the logarithm of the Minimum Angle of Resolution (LogMAR) chart.
Time Frame
28 days
Title
Assess the frequency of second eye infections.
Description
Occurrence of second eye infection.
Time Frame
14 days
Title
Assess the safety and tolerability of APD-209 Eye drops.
Description
Safety variables: adverse events (AEs) (nature and incidence), Physical examination, vital signs, laboratory safety assessments (haematology, clinical chemistry and urinalysis)
Time Frame
14 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patients have to meet all of the following criteria to be eligible to enter the study: Willing and able to provide informed consent. Men or women aged 18 years or above with onset of adenoviral EKC symptoms in at least one eye, as clinically diagnosed and with symptoms appearing within less 7 days at the time of giving informed consent. Using adequate contraceptive measures Exclusion Criteria: Known or suspected allergy to any ingredient of the IMP or placebo. Symptoms correlating with EKC since more than 7 days. Diagnosis of other significant disease(s) than EKC in the eye. Diagnosis of bacterial or fungal ocular infections. Use of antibiotics or corticosteroids by any route (except intravitreal corticosteroids) within 14 days prior to inclusion. Ocular antibiotics may, however, be used until 2 hours prior to first dose of IMP, but are thereafter prohibited during the study. Use of immunosuppressive medications (including intravitreal corticosteroids) within 6 months prior to inclusion. Use of antiviral medications within 7 days prior to inclusion. Usage of any medication or herbal medicinal product with documented adverse reactions affecting the eyes. Usage of any medication or herbal medicinal product for ocular administration at inclusion. Female patients: currently pregnant or breast-feeding or intending to become pregnant during the study period. Known or suspected drug abuse. Usage of contact lenses during the study. Participation in any other interventional clinical study within 30 days prior to inclusion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carl Gustaf Laurell, MD PhD
Organizational Affiliation
St Eriks Eye Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Augenklinik Universitätzmedizin Charité
City
Berlin
ZIP/Postal Code
12200
Country
Germany
Facility Name
Universitätsklinikum Düsseldorf
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Facility Name
Universitäts-Augenklinik Freiburg
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Augenklinik Köln, Merheim
City
Köln
ZIP/Postal Code
51109
Country
Germany
Facility Name
Universitäts-klinikum Schleswig-Holstein
City
Lübeck
ZIP/Postal Code
23538
Country
Germany
Facility Name
Augenklinik, Universitätsklinikum Tübingen
City
Tübingen
ZIP/Postal Code
72026
Country
Germany
Facility Name
Universitäts-Augenklinik
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Facility Name
Katowice University Hospital
City
Katowice
ZIP/Postal Code
40-514
Country
Poland
Facility Name
P. Oleksy Centrum Medyczne Uno-Med
City
Tarnow
ZIP/Postal Code
33-100
Country
Poland
Facility Name
St Eriks Eye Hospital
City
Stockholm
Country
Sweden

12. IPD Sharing Statement

Learn more about this trial

Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)

We'll reach out to this number within 24 hrs